Wolverine Stack

Typical use cases

Dosing guidelines

Titration

Community protocols often describe a higher-frequency "loading" phase for TB-500 (e.g. larger weekly totals for the first few weeks) followed by a lower-frequency maintenance phase, with BPC-157 typically held at a steady daily amount throughout a cycle. Some users report localized/subcutaneous-near-injury dosing for BPC-157 during the loading window. These patterns are reported, not prescribed.

Reconstitution

Both peptides are typically supplied as lyophilized powder reconstituted with bacteriostatic water (0.9% benzyl alcohol) added slowly down the vial wall and gently swirled (not shaken). Where a stack is sold as a single combined vial, both peptides are reconstituted together; where sold separately, each is reconstituted in its own vial. Reconstitution volume is chosen to give a convenient concentration per the user's measured dose.

Injection sites

Subcutaneous injection is most commonly reported (abdomen, flank/love-handle, or upper thigh), with rotation between sites. BPC-157 is sometimes reported as administered subcutaneously near the injured area; intramuscular use is also described in some protocols. TB-500 is typically given subcutaneously or intramuscularly.

Storage & handling

Lyophilized (unreconstituted) vials are generally stored refrigerated (2-8°C) and protected from light; short-term room-temperature exposure is usually tolerated for shipping. Once reconstituted, vials should be refrigerated (2-8°C) and used within a few weeks; avoid freezing reconstituted solution.

Side effects

• Injection-site reaction (redness, irritation, transient pain) Mild · Common
• Fatigue or lethargy Mild · Uncommon
• Headache Mild · Uncommon
• Lightheadedness / transient blood-pressure or flushing sensations Mild · Uncommon
• Nausea or gastrointestinal upset Mild · Uncommon
• Theoretical risk of promoting unwanted/pathologic angiogenesis (e.g. concern with active malignancy) — hypothetical, not established in humans Severe · Rare

Research summary

The Wolverine Stack pairs BPC-157 and TB-500 on the rationale that they act through complementary, non-overlapping repair pathways. BPC-157's preclinical literature describes promotion of angiogenesis (via upregulation of VEGF/VEGFR2 and the Akt-eNOS nitric-oxide axis), enhanced fibroblast outgrowth, survival and migration (FAK-paxillin pathway), increased collagen synthesis, and upregulation of growth-hormone-receptor expression in tendon fibroblasts, with healing benefits shown in rodent models of tendon, ligament, muscle, bone and gastrointestinal injury. TB-500 / thymosin beta-4 is the major intracellular actin-sequestering molecule; by buffering G-actin it enables rapid cytoskeletal remodeling that drives keratinocyte, fibroblast and endothelial-cell migration, with rodent wound models showing markedly increased re-epithelialization, contraction, collagen deposition and angiogenesis. The combined-stack hypothesis is that TB-500 dampens early inflammatory signaling and mobilizes progenitor cells while BPC-157 drives local angiogenesis and fibroblast-mediated matrix synthesis, theoretically covering the inflammation, proliferation and remodeling phases of healing. Critically, the human evidence base is extremely thin: a 2025 narrative review notes only about three small BPC-157 pilot studies in people, and a 2025 orthopaedic systematic review (35 preclinical vs 1 clinical study) concludes the data are largely animal-derived with limited, low-quality human evidence. There are no rigorous randomized controlled trials of the BPC-157 + TB-500 combination, and almost no human pharmacokinetic data; reported synergy is mechanistic and anecdotal rather than trial-proven. Both compounds are unapproved drugs: BPC-157 is WADA-prohibited (2022) and was restricted by the FDA for compounding (2023), and TB-500/thymosin beta-4 is likewise WADA-banned and not an approved therapeutic, with most supply coming from unregulated research-chemical channels where purity and contamination are real concerns. Overall the stack should be regarded as investigational and educational only, with promising preclinical signals but unestablished human efficacy and long-term safety.

Key references

• https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
• https://pubmed.ncbi.nlm.nih.gov/21030672/
• https://pubmed.ncbi.nlm.nih.gov/40756949/
• https://pubmed.ncbi.nlm.nih.gov/20388964/
• https://pubmed.ncbi.nlm.nih.gov/16099219/
• https://pubmed.ncbi.nlm.nih.gov/10469335/

Related compounds